Novel dihydrochalcone from Fissistigma latifolium targets STAT3 and survivin to overcome multidrug resistance cancers in vitro and in vivo
This study highlights DODHC as a dual inhibitor of STAT3 and survivin, demonstrating its potential as a promising candidate for the treatment of MDR cancers.
Authors
- Ying‐Tzu Chang (ORCID: https://orcid.org/0009-0007-9913-1041)
- I‐Ting Wu (ORCID: https://orcid.org/0000-0002-4003-2766)
- Ching‐Hui Su
- Chin‐Chuan Hung (ORCID: https://orcid.org/0000-0003-1395-4834)
- Yu‐Hsuan Lan
Institutions
- Asia University (TW)
- China Medical University (TW)
- China Medical University Hospital (TW)
Publication Details
- Journal
- Biomedicine & Pharmacotherapy
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1016/j.biopha.2025.118125
- Citations
- 1
- Primary Topic
- Bioactive Compounds and Antitumor Agents
- Type
- article
- Field-Weighted Citation Impact
- 1.31
Funders
- China Medical University
- China Medical University, Taiwan